Literature DB >> 2548759

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart.

J A Hall1, M C Petch, M J Brown.   

Abstract

To demonstrate the presence of functional cardiac beta 2-adrenoceptors in man, we studied the responses to intracoronary injections of salbutamol in three groups of six patients. We injected salbutamol, a selective beta 2-adrenoceptor agonist, into the right coronary artery to avoid peripheral vasodilator action and to stimulate the sinoatrial node directly. Salbutamol injections caused a sinus tachycardia. The same doses of salbutamol injected into the aortic root caused no change in heart rate, ruling out a systemic effect. The mean dose required to cause an increase in heart rate of 30 beats/min (IHR30) was 2.6 micrograms in the first group of six patients. In 12 other patients salbutamol was given after beta-blockade to confirm the beta 2-selectivity of the responses. Doses of practolol (beta 1-selective blockade) and of propranolol (beta 1- and beta 2-blockade) that had equal beta 1-blocking activity were used. In six patients who were given practolol, the mean IHR30 dose was 2.1 micrograms. In six patients who were given propranolol, the mean IHR30 dose was significantly greater at 64 micrograms (p less than 0.001, practolol vs. propranolol). This study demonstrates that direct cardiac beta 2-adrenoceptor stimulation in man has a positive chronotropic effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548759     DOI: 10.1161/01.res.65.3.546

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  34 in total

Review 1.  A rational basis for selection among drugs of the same class.

Authors:  Morris J Brown
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

2.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  Dose-response study with high-dose inhaled salmeterol in healthy subjects.

Authors:  J G Maconochie; J K Forster
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

4.  Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects.

Authors:  B J Lipworth; B F Tregaskis; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects.

Authors:  D K Rohrer; K H Desai; J R Jasper; M E Stevens; D P Regula; G S Barsh; D Bernstein; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

6.  The cardiovascular effects of beta adrenergic agonist drugs administered by nebulization.

Authors:  J A Hall
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

7.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

8.  To beta block or better block?

Authors:  M J Brown
Journal:  BMJ       Date:  1995-09-16

9.  Beta 1- and beta 2-adrenoceptor-mediated relaxation in human internal mammary artery and saphenous vein: unchanged beta- and alpha-adrenoceptor responsiveness after chronic beta 1-adrenoceptor blockade.

Authors:  A Ferro; A J Kaumann; M J Brown
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects.

Authors:  D M Newnham; N M Wheeldon; B J Lipworth; D G McDevitt
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.